Nagoya University researchers and their collaborators have found that minimally invasive laparoscopic surgery significantly reduces blood loss and improves jaundice recovery compared to traditional ...

Biliary atresia is a rare, life‐threatening congenital disorder marked by the obliteration or absence of bile ducts, which leads to cholestasis and rapid progression to cirrhosis if left untreated.

My baby was diagnosed with biliary atresia when he was 2 months old. While Google helped me identify his symptoms, it was a doctor who listened and diagnosed him. He had surgery to repair his bile ...

Nagoya University researchers and their collaborators have found that minimally invasive laparoscopic surgery significantly reduces blood loss and improves jaundice recovery compared to traditional ...

Please provide your email address to receive an email when new articles are posted on . Healio spoke with Ahmad Anouti, MD, about a presentation at The Liver Meeting on the prognostic value of ...

This study found significant inter-hospital variability in the age at which Kasai portoenterostomy for biliary atresia is performed in tertiary children's hospitals in the United States. Improved ...

Biliary atresia (BA) is a life-threatening liver disease of infancy in which early surgery can restore bile flow but rarely halts long-term liver injury.

Biliary atresia (BA) is a rare but life-threatening neonatal liver disorder marked by bile duct obstruction. While most cases occur in isolation, a subset is linked with other congenital ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), today announced top-line results of the Phase 2 EMBARK study evaluating LIVMARLI® (maralixibat) oral solution versus ...

BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--CANbridge Pharmaceuticals Inc. (HKEX:1228), a leading China and US-based global biopharmaceutical company committed to the research, development and ...

- Study did not meet primary or secondary endpoints. - LIVMARLI was generally well-tolerated, with no new safety findings. FOSTER CITY, Calif.--(BUSINESS WIRE)-- Mirum Pharmaceuticals, Inc. (Nasdaq: ...